Late treatment of murine lupus erythematosus with dactinomycin. II. C1 and antibody to DNA

(NZB x NZW)F1 hybrid (B/W) female mice were treated intermittently with dactinomycin beginning at 6--6.5 months of age. Survival was greatly prolonged relative to control mice. IgG antibody to DNA did not decline significantly in the treated mice until they were more than 18 months old, but circulat...

Full description

Saved in:
Bibliographic Details
Published inImmunology Vol. 43; no. 2; pp. 213 - 217
Main Authors Olsen, C T, Teague, P O, Gabrielsen, A E
Format Journal Article
LanguageEnglish
Published England 01.06.1981
Subjects
Age Factors
Animals
Antibodies, Antinuclear - analysis
Complement C1 - analysis
Dactinomycin - therapeutic use
DNA - immunology
Female
Lupus Erythematosus, Systemic - drug therapy
Lupus Erythematosus, Systemic - immunology
Mice
Time Factors
Online AccessGet full text

Cover

More Information
Summary:(NZB x NZW)F1 hybrid (B/W) female mice were treated intermittently with dactinomycin beginning at 6--6.5 months of age. Survival was greatly prolonged relative to control mice. IgG antibody to DNA did not decline significantly in the treated mice until they were more than 18 months old, but circulating levels of the first complement component (Cl) rose during the first 4 weeks of treatment and were back into the normal range after 8 weeks. Thus these two humoral indexes of disease activity varied independently, and only Cl reflected the improved status of the treated mice.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ObjectType-Article-1
ObjectType-Feature-2
ISSN:0019-2805
1365-2567